Lilly's experimental drug shows superiority over Zepbound in weight-loss trial
Eli Lilly announced that its experimental combination weight-loss drug demonstrated superior performance compared to its own blockbuster drug, Zepbound, in a head-to-head trial. This intensifies competition in the obesity therapy market.